本帖最后由 老马 于 2013-3-13 13:43 编辑
# z% e" p3 [% @, a' O7 a4 K' z \0 w. W6 P2 F& m8 `1 P
健择（吉西他滨）+顺铂+阿瓦斯汀
' R5 c% I) Z: Q' F Gemzar +Cisplatin + Avastin3 Q8 E! n7 E' L1 N
http://annonc.oxfordjournals.org/content/21/9/1804.full. h9 q. G& W/ [& Y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; {/ ?* d! I. F- H: ~& Y: GPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - A" h" ?; b' L6 B4 z. P: D4 L
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. # P' B! s$ g) ]8 d% A& m, e
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 639)
& K4 d6 U2 t. k$ F华为网盘附件：
' r: o4 L+ L; a( J/ y5 n# r3 Q4 R0 ?【华为网盘】ava.JPG
L0 m1 g7 T# y& L* F' g |
显身卡
